The Journal of Immunology, Vol 156, Issue 8 2700-2709, Copyright © 1996 by American Association of Immunologists

ARTICLES

Interactions of CD80 and CD86 with CD28 and CTLA4

JH Ellis, MN Burden, DV Vinogradov, C Linge and JS Crowe
Immunopathology Unit, Glaxo-Wellcome Medicines Research Centre, Hertfordshire, United Kingdom.

CD80 and CD86 are cell surface glycoproteins expressed on a variety of professional APCs. They have attracted much attention due to their function as potent costimulators of T lymphocyte function through their interaction with CD28 and possibly CTLA4. Because inhibitors of this interaction may have therapeutic relevance in human autoimmune disease, we investigated the properties of linear peptides derived from conserved regions of CTLA4 and CD80 known to be essential for binding. None of these peptides were sufficient to bind ligand, nor did they act as potent competitive inhibitors. Conformationally constrained versions of the CTLA4 motif were also inactive. These results suggested that other parts of the proteins are important in determining binding, so a series of modified CD80 and CD86 molecules were constructed in an attempt to identify other binding determinants. Insertion of two residues between the two Ig domains of CD80 resulted in decreased affinity for CTLA4, but a similar mutation in CD86 was without effect. We also identified another asymmetry between CD80 and CD86 in that the V domain of CD86 but not that of CD80 is sufficient for CTLA4 binding. The CD86-V domain appears to have CTLA4 binding properties equivalent to that of intact CD86. These data illustrate a fundamental difference between these costimulatory molecules and suggest a mechanism by which they may be differentially recognized by receptors on the T cell surface.

This article has been cited by other articles:

				P. Sorensen, M. Kussmann, A. Rosen, K. L. Bennett, D. d. G. Thrige, K. Uvebrant, B. Walse, P. Roepstorff, and P. Bjork Identification of Protein-Protein Interfaces Implicated in CD80-CD28 Costimulatory Signaling J. Immunol., June 1, 2004; 172(11): 6803 - 6809. [Abstract] [Full Text] [PDF]

				M. G. Agadjanyan, M. A. Chattergoon, M. J. Holterman, B. Monzavi-Karbassi, J. J. Kim, T. Dentchev, D. Wilson, V. Ayyavoo, L. J. Montaner, T. Kieber-Emmons, et al. Costimulatory Molecule Immune Enhancement in a Plasmid Vaccine Model Is Regulated in Part Through the Ig Constant-Like Domain of CD80/86 J. Immunol., October 15, 2003; 171(8): 4311 - 4319. [Abstract] [Full Text] [PDF]

				X. Zhang, J.-C. D. Schwartz, S. C. Almo, and S. G. Nathenson Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling PNAS, March 4, 2003; 100(5): 2586 - 2591. [Abstract] [Full Text] [PDF]

				C. Vasu, A. Wang, S. R. Gorla, S. Kaithamana, B. S. Prabhakar, and M. J. Holterman CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties Int. Immunol., February 1, 2003; 15(2): 167 - 175. [Abstract] [Full Text] [PDF]

				J.-F. Giguere, J.-S. Paquette, S. Bounou, R. Cantin, and M. J. Tremblay New Insights into the Functionality of a Virion-Anchored Host Cell Membrane Protein: CD28 Versus HIV Type 1 J. Immunol., September 1, 2002; 169(5): 2762 - 2771. [Abstract] [Full Text] [PDF]

				M. Srinivasan, R. M. Wardrop, I. E. Gienapp, S. S. Stuckman, C. C. Whitacre, and P. T. P. Kaumaya A Retro-Inverso Peptide Mimic of CD28 Encompassing the MYPPPY Motif Adopts a Polyproline Type II Helix and Inhibits Encephalitogenic T Cells In Vitro J. Immunol., July 1, 2001; 167(1): 578 - 585. [Abstract] [Full Text] [PDF]

				C. S. Heinly, G. D. Sempowski, D. M. Lee, D. D. Patel, P. M. McDermott, R. M. Scearce, C. B. Thompson, and B. F. Haynes Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice Int. Immunol., February 1, 2001; 13(2): 157 - 166. [Abstract] [Full Text] [PDF]

				J. H. Ellis, C. Ashman, M. N. Burden, K. E. Kilpatrick, M. A. Morse, and P. A. Hamblin GRID: A Novel Grb-2-Related Adapter Protein That Interacts with the Activated T Cell Costimulatory Receptor CD28 J. Immunol., June 1, 2000; 164(11): 5805 - 5814. [Abstract] [Full Text] [PDF]

				H Amano, S Morimoto, H Kaneko, Y Tokano, Y Takasaki, and H Hashimoto Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers Lupus, January 1, 2000; 9(1): 26 - 32. [Abstract] [PDF]

				R. J. Greenwald, J. F. Urban, M. J. Ekkens, S.-J. Chen, D. Nguyen, H. Fang, F. D. Finkelman, A. H. Sharpe, and W. C. Gause B7-2 Is Required for the Progression But Not the Initiation of the Type 2 Immune Response to a Gastrointestinal Nematode Parasite J. Immunol., April 1, 1999; 162(7): 4133 - 4139. [Abstract] [Full Text] [PDF]

				J. M. Slavik, J. E. Hutchcroft, and B. E. Bierer CD80 and CD86 Are Not Equivalent in Their Ability to Induce the Tyrosine Phosphorylation of CD28 J. Biol. Chem., January 29, 1999; 274(5): 3116 - 3124. [Abstract] [Full Text] [PDF]